U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.Shares of Novo Nordisk A/S (NYSE:NVO) fell sharply in today's pre-market trading after Evoke Phase 3 trials data showed that GLP-1 drugs did not demonstrate statistically significant reduction in Alzheimer’s disease progression.Novo Nordisk shares dipped 9.3% to $43.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Geospace Technologies Corp (NASDAQ:GEOS) shares tumbl ...